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Patients’ lived experiences with antineoplastic medicines for the management of malignant solid 1 
tumours: a systematic review 2 
 3 
Abstract 4 
 5 
Background: Antineoplastic medicines affect the patients’ physical and psychosocial well-being posing 6 
challenges for patients, caregivers and healthcare professionals. However, little is known about the 7 
patients’ lived experience with medicines (PLEM) for antineoplastic treatment.  It is the lived experience 8 
that gives meaning to each individual’s perception of a particular phenomenon which is influenced by 9 
internal and external factors relevant to the individual.  10 
 11 
Objectives: To critically appraise, synthesise and present the available evidence of patients’ lived 12 
experience with antineoplastic medicines prescribed for the management of malignant solid tumours. 13 
 14 
Method: A systematic literature search was conducted in six electronic databases for articles published in 15 
English with no date restrictions. The search terms were related to beliefs, practice and burden in relation 16 
to patient, antineoplastic medicines, tumours and lived experience. Study selection, quality assessment 17 
and data extraction were performed independently by 2 reviewers. Research findings were analysed using 18 
narrative and meta-synthesis approaches.  19 
  20 
Results: The search retrieved 31,004 articles with only 10 studies satisfying the inclusion and exclusion 21 
criteria. These studies were published between 2005 and 2016 in Europe (n=6), America (n=3) and Asia 22 
(n=1). Nine themes were identified to contribute to the patients’ lived experience with antineoplastic 23 
medicines. These were (a) influence from family members, healthcare professionals, media and culture, 24 
(b) general attitude towards medicine, (c) accepting medicine, (d) modifying or altering medicine regimen 25 
or dose, (e) medicine characteristics, (f) medicine routine, (g) medicine adverse events, (h) medicine and 26 
social burden and (i) healthcare associated medicine burden. Patients tend to undergo a continuous 27 
process of reinterpretations of their experience with medicines throughout their treatment journey. 28 
 29 
Conclusion: The use of antineoplastic medicines has a profound effect on the patients’ lives. Further 30 
longitudinal in-depth studies are required to provide deeper insight into PLEM and support patients in 31 
their treatment journey.  32 
 33 
 Keywords: solid tumor; antineoplastic medicines; patients’ lived experience with medicine;                   34 
medicine-taking practice; medicine-related beliefs; medicine-related burden 35 
 36 
 37 
Abbreviations: 38 
PLEM - Patients’ Lived Experience with Medicines  39 
CASP - Critical Appraisal Skills Programme  40 
EPHPP - Effective Public Health Practice Project  41 
PRISMA-P - Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol 42 
PROSPERO - International Prospective Register of Systematic Reviews  43 
44 
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Introduction  45 
Cancer is a group of related diseases featured by uncontrolled growth and dissemination of abnormal 46 
cells; with more than 80% of all cancers being solid tumours.1,2 Cancers with the highest incidence 47 
amongst both genders are solid tumours in the breast, lung, colorectum and prostate. More than 18 million 48 
patients were newly diagnosed with cancer worldwide in 2018.3 It is being projected that by 2030 the 49 
number of newly diagnosed cancer cases will rise to over 22 million per year predicted on the basis of an 50 
aging population and adoption of behaviours linked with socio-economic development. Hence it is being 51 
considered as an enormous international health burden growing at an alarming pace. 2,4,5 52 
 53 
Antineoplastic medicines, which are often used as part of the treatment in combination with surgery and 54 
radiation, interfere with cell growth resulting in apoptosis of cancer cells. Over the years, advances in 55 
cancer care have led to prolonged cancer remission and management even when cure cannot be achieved. 56 
Hence cancer is being considered as a chronic condition.2,6  The number of cancer survivors in America is 57 
expected to increase from 15.5 million in 2015 to 20 million by 2026.7   58 
 59 
Patients, themselves, are primarily responsible for the management of their health. Patient participation 60 
within the healthcare systems includes the involvement of the patient in decision making, expressing 61 
opinions about different treatment methods such as sharing of information, feelings and cooperating with 62 
the healthcare professionals’ advice. The concept of enabling active patient participation is increasingly 63 
noted as a key component in the redesign of healthcare services and also as means to improve patient 64 
safety.8, 9  65 
 66 
The medicine experience incorporates the patient’s description of his expectations, concerns, beliefs, 67 
cultural, ethical and religious influences on medicine-taking behaviour.  Cipolle et al. (2004) developed 68 
the concept of medicine experience defined as “the sum of all the events a patient has in his/her lifetime 69 
that involves drug therapy.”  This approach is emphasised in the practice of pharmaceutical care as it 70 
focuses on patient-centred approach by providing direct care to patients based on their medicine-related 71 
needs.10 Similarly, Shoemaker and Ramalho de Oliveira in 2008 defined “the medication experience as an 72 
individual’s subjective experience of taking a medication in his daily life.”11 The concept of lived 73 
experience stresses the fact that only those who have experienced the phenomena can communicate their 74 
real experience to the outside world.12,13  A conceptual model of patients’ lived experience with medicines 75 
was compiled in a metasynthesis of qualitative studies by Mohammed et al. (2016). As depicted in                         76 
Figure 1, this incorporated medicine-related burden, medicine-related beliefs and medicine-taking 77 
practice. These concepts will in turn affect the patients’ wellbeing and health-related quality of life 78 
together with therapeutic outcomes.14 79 
 80 
Healthcare professionals’ behaviours, family members and peers influence the patient’s beliefs towards 81 
medicines. The intensity of medicine-related burden and the coping skills of the individual influence the 82 
patient’s attitude and behaviour to the use of medicines. Positive attitudes arise from trust in healthcare 83 
professionals, positive medicine experience and achievement of the desired therapeutic outcomes. The 84 
medicine-related beliefs with the effect of the medicine-related burden influence the medicine-taking 85 
practice.14,15 Medicine-related burden incorporates the medicine regimen, characteristics, adverse events 86 
together with the social and healthcare effects. Mohammed et al. (2016) showed that intolerable medicine 87 
burden often resulted in non-adherence and poor treatment outcomes.14 In addition, a study on 97 88 
Australian participants identified medicine-related burden as one of 4 interrelated components of 89 
treatment burden (financial, time, travel and healthcare access burden) operating in a cyclical manner.16  90 
 91 
The focus of cancer care is centred on improving patient experience by understanding the burden they 92 
meet in everyday life, as well as the unmet needs of treatment such as treatment adverse effects and 93 
quality of life. These insights can be achieved through direct and constructive interactions with 94 
patients.9,17    95 
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 96 
The increasing number of publications including systematic reviews in the field of oncology indicates that 97 
the care of cancer patients persists as a clinical research priority.  The majority of the systematic reviews 98 
evaluated cancer drug treatment effectiveness, safety and supportive care interventions.18 Despite this, 99 
systematic reviews about medicine experiences of adult cancer patients undergoing antineoplastic 100 
treatment are lacking. The aim of this systematic review was to critically appraise, synthesise and present 101 
the available evidence of patients’ lived experiences of antineoplastic medicines prescribed for the 102 
management of malignant solid tumours. 103 
Method 104 
Protocol registration 105 
A systematic review protocol was developed in accordance with the Preferred Reporting Items for 106 
Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) standards.19 The protocol was then 107 
registered with International Prospective Register of Systematic Reviews (PROSPERO) 108 
[PROSPERO2016:CRD42016048457] to avoid unplanned duplication of work.20  109 
Eligibility criteria 110 
Studies were included in the systematic review if: 111 
• the recruited patients were aged ≥18 years irrespective of their gender, ethnicity and stage of disease 112 
and were receiving antineoplastic medicines for the management of malignant solid tumours in any 113 
setting; and 114 
• the views, experiences and behaviours of patients in receiving antineoplastic medicines from their 115 
perspective were reported; and 116 
• the study incorporated all the 3 aspects of the patients’ lived experience with medicines concept: 117 
medicine-related beliefs, medicine-related burden and medicine-taking practice as outcome measures. 118 
 119 
Studies were excluded if they investigated the patient experience in experimental studies rather than the 120 
‘real world’ setting, they included experiences of patients taking antineoplastic medicines solely for 121 
palliative intent, studies reported in a non-English language or published as conference abstracts and grey 122 
literature.  123 
Search strategy  124 
A database search strategy using specified search terms and their different combinations was created in 125 
consultation with the research team. The key concepts of the patients’ lived experience with medicines, 126 
extracted from the model developed by Mohammed et al. (2016), were medicine-related burden, medicine 127 
related-beliefs and medicine-taking practice.  The search focused on these concepts in relation to patient, 128 
antineoplastic medicines, malignant solid tumours and lived experience. Concept mapping was utilised as 129 
an aid to consider all aspects of the topic and identify keywords that may be used for the search. The 130 
search strategy was then adapted to meet the specifications of the different databases.   131 
A systematic literature search was conducted in six databases: Cumulative Index to Nursing and Allied 132 
Health Literature (CINAHL), Medline, Cochrane Database of Systematic Reviews, Embase, International 133 
Pharmaceutical Abstracts and PsycArticles. The manual search of related studies in the references of 134 
identified publications was carried out to identify additional potentially relevant papers.   135 
Study Review 136 
Screening was performed first on titles, then on abstracts and then followed by full papers in accordance 137 
to the inclusion and exclusion criteria.  A random sample of 10% of the retrieved titles and abstracts and 138 
the whole list of full papers were screened independently by 2 members of the research team for 139 
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consistency of inclusion/exclusion and to enhance the reliability of the process. Any disagreement was 140 
resolved following discussion and consensus was reached within the research team.  141 
Quality assessment  142 
Studies were appraised using quality appraisal forms adapted from the Critical appraisal skills programme 143 
(CASP)21 and Equator Network22 for qualitative research together with the quality assessment tool of the 144 
Effective public health practice project (EPHPP) for quantitative research.23 Quality assessment was 145 
performed independently by 2 reviewers.  Any disagreements were discussed and resolved by consensus.   146 
Data extraction and synthesis of results 147 
Data extracted from the articles included specific details about the populations, study setting, research 148 
design, method, salient findings and study limitations. The research findings of the quantitative and 149 
qualitative studies were analysed using narrative and meta-synthesis approaches respectively. This 150 
systematic review implemented the qualitative meta-interpretative synthesis (QIMS) methodology for 151 
qualitative studies in an attempt to “create a new, deeper, and broader understanding” of the 152 
phenomenon.24 QIMS allows the extracted data to be analysed through a process of coding, theme 153 
extraction, theme synthesis and triangulation.25,26 After repeatedly reading the included studies, sections 154 
identified to fall within one of the 3 main categories: (1) medicine-related beliefs, (2) medicine-taking 155 
practice and                           (3) medicine-related burden in accordance to the model of Mohammed et al. 156 
(2016) were extracted and reported verbatim in line with the corresponding theme. The quotes, if 157 
available, were pulled directly from the study. This was independently done by the first researcher and 158 
another researcher within the team to ensure that all extracts within the study were identified and grouped 159 
in the same category. Then the studies were translated into each other. Proposed themes and sub-themes 160 
were put forward by all researchers through an iterative process.  The theme synthesis process utilises 161 
triangulation to enhance dependability and trustworthiness of the findings. Triangulation is based on 4 162 
processes, namely methods, sources, analysts and theoretical perspectives.24,25   163 
Bias 164 
The risk of bias was minimised by the application of the following measures: 165 
• A random sample of 10% of studies identified during the database search was independently 166 
assessed for relevance by two independent reviewers.  167 
• Quality assessment using standardised critical appraisal instruments and data extraction of all 168 
selected papers was conducted by two independent reviewers prior to inclusion in the review. 169 
• Disagreements were resolved by consensus after discussion with the research team.  170 
 171 
Results 172 
Study selection 173 
As shown in the Prisma flow diagram27 (Figure 2), the combined search yielded 31,004 titles. A total of 174 
10 studies met the inclusion criteria and were included in the systematic review.28-37 Two studies were 175 
quantitative studies and 8 studies followed qualitative methodology.  176 
Description of the selected studies 177 
The characteristics of the included studies are summarised in Table 1. Studies were published between 178 
2005 and 2016 and were conducted on 3 continents: Europe (n=6), America (n=3) and Asia (n=1). 179 
Sample sizes ranged from 1 to 92 participants. Qualitative studies were conducted on 153 patients in total 180 
whilst quantitative studies investigated 154 patients. Four studies included solely male participants whilst 181 
only 1 study involved only female participants in the sample population.  Six studies investigated patients 182 
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suffering from a single cancer type: advanced non-small cell lung cancer (2 studies), breast cancer (3 183 
studies) and colorectal cancer (1 study). The remaining 4 studies did not focus on any particular cancer 184 
type but involved patients suffering from various solid tumours.  The treatment strategy varied across all 185 
10 studies. Two studies focused on patients receiving capecitabine, two studies included patients 186 
receiving erlotinib or completed adjuvant antineoplastic treatment (fluorouracil, epirubicin and 187 
cyclophosphamide treatment protocol) respectively and the other six studies involved patients receiving 188 
different antineoplastic treatment protocols.  189 
The majority of studies (n=8) used a range of qualitative methods which included focus groups (1 study), 190 
open interviews (2 studies), semi-structured interviews (2 studies) or multi-method approach consisting of 191 
observational study with semi-structured interviews with or without the use of field diary (3 studies).  192 
Two further studies used a quantitative approach where data was collected using patient-reported ques-193 
tionnaires, blood sampling and patient’s medical files. 194 
 195 
Out of the 10 studies, 3 studies did not state at which point in the patient’s cancer journey the interview 196 
was conducted. Six studies collected data during the patient’s treatment phase whilst 1 study took a 197 
retrospective look at patients who had completed chemotherapy within the previous year. Qualitative data 198 
of included studies were analysed using content analysis, grounded theory and ethnography. Hence this 199 
systematic review satisfied the 4 triangulation processes.   200 
Quality assessment of the included studies 201 
The quality assessment of the included studies is summarised in Appendices 1-4. The strengths of the 202 
studies included a clear research aim in 80% (n=8) of the studies, an appropriate study design and the 203 
attainment of ethical approval in all the studies except one where it was unclear whether ethical approval 204 
was granted. The results obtained in the majority of the studies (n=8) clearly addressed the original 205 
research question and the key findings were explained in detail. 206 
The weaknesses of the selected studies included the lack of justification for the final sample size in the 207 
manuscript (n=2) and the lack of discussion on the limitations of findings such as triangulation, bias and 208 
confounders (n=8).  The latter clarifies the extent to which the findings offer an accurate representation of 209 
the phenomenon under study, hence affecting the validity and reliability of research findings.  210 
Data synthesis  211 
The studies included in this systematic review did not provide a standard definition of the patients’ lived 212 
experience with medicine. Nine themes emerged to highlight the patients’ lived experience with 213 
antineoplastic medicines in patients suffering from solid tumours: medicine-related beliefs (two themes), 214 
medicine-taking practice (two themes) and medicine-related burden (five themes). The themes and 215 
subthemes generated from this systematic review were mapped and presented in line with the structure of 216 
the PLEM model (Figure 3) adapted from the conceptual model of Mohammed et al. (2016). 217 
Modifications in the adapted model included the elimination of medicine related burden, magnitude and 218 
coping skills from the main theme of medicine-related beliefs and the inclusion of the sub-themes within 219 
the model to ensure a clear understanding. 220 
Medicine-related beliefs 221 
The identified themes within medicine-related beliefs included (a) influence of healthcare professionals, 222 
family members, media and culture as well as (b) general attitude towards medicine.  223 
(a) Influence of family members, healthcare professionals, media and culture 224 
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Chemotherapy, as a treatment, was found to be unique in being considered “as the source of suffering” 225 
both culturally and medically.31 Suffering encompassed both a meaning and a value for each cancer 226 
patient. The myths and stigma associated with cancer treatment may have silencing effects and may 227 
influence the patient’s behaviour resulting in patients seeking support at a later stage of treatment.28, 31 228 
 229 
Patients tend to follow the healthcare professionals’ treatment recommendation to base their decision on 230 
whether to initiate treatment or not. The trust of the patient in the healthcare professionals’ attitudes and 231 
their relationship act as a driving force in their treatment decision and has a strong positive influence on 232 
compliance with the medicine.28,33 “I don’t know if I’m that brave yet, but if my doctors assured me this 233 
was a good move, this was a good move for me, I feel confident enough in [my doctor] to follow his 234 
advice.”33 235 
 236 
Family members have also shown to be highly influential on patients’ beliefs and this was reflected in the 237 
patients’ decisions regarding treatment. Patients disclosed their feelings of responsibility towards their 238 
family members as they felt obliged to survive even if this was associated with suffering and 239 
restrictions.33,35  240 
“Yes, I just thought that if something comes back again and I say no, then I have to look my family and 241 
friends in the eye and say I could have prevented it, perhaps. Now, if something comes back again, I can 242 
say I did everything I could. Cancer is bad enough without someone saying: It’s your own fault!!”35   243 
 244 
Media and support groups have been found to strongly influence the cancer patient’s beliefs. Newly 245 
diagnosed cancer patients may even obtain a false picture about cancer and its treatment from these 246 
sources and this may provoke unnecessary anxiety.29, 31 Cultural aspects also affect patients’ outlook on 247 
cancer and its treatment as different cultures have diverse views on life, death and pain in general. 28, 31 248 
 249 
(b) General attitude of the patient towards medicine 250 
Chemotherapy is considered as one of the current treatment strategies that may lead to a disease-free 251 
future and ultimately to survival.28 Studies showed that prior to the initiation of treatment patients already 252 
had pre-conceived notions and expectations about their treatment. A commonly expressed idea amongst 253 
patients is that chemotherapy “hurt the good cells and really hurting the cancer cells.”30,31,35 Several 254 
feelings were expressed by patients at initiation of treatment with antineoplastic medicines. These 255 
included hope28,33, anxiety, stress 29,35, fear and also acceptance to carry the burden of side effects.35  It 256 
was noted that although chemotherapy provides grounds for “hope”33, this is a highly feared form of 257 
treatment that is commonly considered to be as bad or worse than the experience of cancer itself.30,31 258 
Patients expressed concerns related to aesthetic adverse effects such as hair loss, feeling of sickness and 259 
dependency on intake of medicines.30 “When I found out that I was going to have chemotherapy my whole 260 
world came apart. It was the worst thing I could imagine.” 30 As treatment cycles progressed, patients 261 
reported to feel calmer and more peaceful (mean value of the mental component of SF-12 Health Survey 262 
improved from 47.1±7.5 at baseline to 50.4±5.4 at cycle 5).37 263 
 264 
When looking to the future, patients pondered if their current chemotherapy would be successful or 265 
whether they would require to continue or change treatment. Patients were also concerned about the 266 
frequency of follow-up visits with the oncologist, the monitoring of symptoms in relation to the disease 267 
and the adverse effects in relation to treatment.28,29  Notwithstanding the fact that the negative feelings 268 
particularly in relation to the side effects symptoms were still fresh in the patients’ minds, patients were 269 
worried about their ability to continue with further chemotherapy sessions whilst coping with experience 270 
of their previous treatment.29 “...But I can’t think about if I were to find out that the cancer had spread, 271 
(and if I were to need more treatment)—how would I then manage to go through chemotherapy again, 272 
now that I know about everything, now that I have all the answers.”29 At the same time however they 273 
anticipated the time when their treatment would be completed and were looking forward to a normal life. 274 
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Some patients argued that they perceived their life to have changed forever and were concerned about 275 
continuing to live their life without treatment but with a lack of energy and a fear of disease recurrence. 276 
“After treatment I want to begin with a trip to the archipelago (islands that lie outside Stockholm) 277 
because that is where I get strength, and I come out of there different, if you compare it to when you are 278 
in the city or town. I have been so close to death and gone through this treatment—well, it is present all 279 
the time..I am going through counselling right now, since I don’t want to put my family through the 280 
motions all the time..”29 281 
 282 
Medicine-taking practice 283 
The themes generated in relation to medicine-taking practice were (a) accepting medicine and (b) 284 
modifying or altering medicine regimen or dose.  285 
(a) Accepting medicine  286 
Qualitative studies revealed that upon receiving the news of suffering from the life-threatening condition 287 
of cancer, the focus shifted from diagnosis to treatment and survival.35 Patients also wanted to know the 288 
intent of treatment to be able to decide whether to undergo treatment and live longer; “if this disease has 289 
no cure you can tell me, because in this case I do not wish any treatment. …He told me that that depends 290 
on the case: if the disease is already too advanced, it is not worth to treat!” 28  291 
 292 
Patients claimed to be highly adherent to antineoplastic medicines.32,34,35 Quantitative studies in patients 293 
receiving erlotinib showed that the mean adherence was 96.8% ± 4.0. 34 Using the pill count method 294 
patients treated with capecitabine showed a high adherence rate with only 8% (n=7) consuming less than 295 
95% of treatment whilst one patient was taking “more than 105% of the prescribed dose.”  .37  296 
The treatment-free period between treatment cycles was medically prescribed interruption from treatment 297 
either in accordance with the treatment protocol or due to adverse effects. Patients associated these breaks 298 
as periods of relief and freedom from constraints to the medicine plan such as “holidays”35 or as 299 
burdensome periods with adverse effects with “fear of recurrence.”33 This emphasised the importance of 300 
involving the patient in treatment decision making and explanation of treatment.  301 
 302 
Along the treatment journey, patients were building up their knowledge about the effects of 303 
chemotherapy, interpreting the physical reactions experienced and developing coping mechanisms. Hence 304 
these patients underwent a continuous process of reinterpreting their situation.28 Collectively, patients 305 
described the treatment journey in cancer as a “degrading experience and anxiety-provoking” as these 306 
patients had to manage various side effects along the treatment phase. A fear of “change” was highly 307 
emphasised; this did not only include the physical appearance especially in women but also the loss of the 308 
normal routine and their identity as they may be considered as a cancer case.29, 30 Although patients were 309 
learning to accept the illness, they still wanted to maintain control over their body. 30 310 
 311 
(b) Modifying or altering medicine regimen or dose 312 
Patients, especially those receiving parenteral chemotherapy treatment, expressed their concern regarding 313 
dose reduction and postponement of chemotherapy regimen by healthcare professionals.31 “When the 314 
oncologist offered to administer more chemotherapy cycles with a lowered dose, she enquired whether 315 
this would still provide the optimal benefit and the oncologist replied “They’ve lowered lots of 316 
people”...She was scared and had enquired with the oncologist whether this will cause the cancer to grow 317 
faster.”31 Self-reported non-adherence measured by MARS showed increasing rates of modifications in 318 
treatment over time ranging from 16% (n=12) at cycle 1 to 29% (n=16) at cycle 5.37 Qualitative 319 
comments noted that cancer patients receiving oral antineoplastic medicines may self-alter their 320 
prescribed treatment regimen resulting in either under or over dosing of the treatment. The underdosing 321 
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phenomenon may occur by unintentionally missing or deliberately skipping a dose to reduce the severity 322 
of unbearable adverse effects such as gastrointestinal symptoms. On the other hand, overdosing may 323 
occur when some patients claimed to consume the remaining forgotten medicines at the end of the cycle 324 
and a patient even admitted that “he did not always respect the break in-between cycles.”32,34,37  Delays in 325 
chemotherapy schedule and dosage reduction have instilled fears in making the tumour “grow faster” and 326 
promote recurrence. Most people receiving cytotoxic chemotherapy seek to obtain certainty over 327 
uncertainty. The importance of taking treatment exactly as prescribed and receiving “100% dose” was 328 
emphasised by the majority of patients.31,32   329 
 330 
Medicine-related burden  331 
Five themes emerged for medicine related burden, these were (a) medicine characteristics (b) medicine 332 
routine (c) medicine adverse events (d) medicine and social burden (e) healthcare associated medicine 333 
burden.   334 
(a) Medication characteristics  335 
The patients’ experience in relation to medicine characteristics was adversely influenced by the dosage 336 
form of treatment,31 colour of the parenteral infusion bag 29 and tablet size.35 Patients recalled their 337 
physical revulsion to the intake of oral antineoplastic formulation due to the size and form of the tablets 338 
that may be too difficult to swallow, profound throat discomfort and the metallic after-taste.35  339 
 340 
Patients remarked that watching the nurse wearing the personal protective wear and following the 341 
procedure to initiate the parenteral infusion created an appalling experience to the patient. This made 342 
them recall that ultimately they would be experiencing adverse effects from such treatment. A patient 343 
metaphorised his feeling as being “chained” to the infusion line.“Especially the moment when the nurse 344 
entered the room wearing protective gear and started the infusion, to be hooked up and to see the 345 
chemotherapy infuse the blood vessel, and to know that this also will give some side effects was a 346 
terrifying experience.” 29 347 
 348 
(b) Medicine routine  349 
In the qualitative studies, medicine routine burden considered aspects that related to the identification of 350 
challenges in adapting to the incorporation of antineoplastic treatment into the patient’s lifestyle and 351 
strategies to overcome these challenges. Patients made great effort to adhere to the prescribed doses and 352 
schedules of chemotherapy due to the continuous awareness of the life-threatening nature of the illness 353 
metaphorised as “pills dominate the mind.”32, 35  This attitude was the “only task that was not delegated to 354 
others” as they felt that they “invested all their energy” so as to feel “actively engaged in fighting against” 355 
cancer.35   356 
 357 
It appears that patients develop individualised treatment strategies to assist them with the adherence 358 
procedure such as counting of tablets, preparing the tablets from the day before, storing the medicinal 359 
product in a “clearly visible prominent place” or setting alarm on their mobile phone. More than 70% of 360 
patients stated that they relied on the reminder method to support their treatment regimen.  No association 361 
was established between adherence as monitored with Medication Event Monitoring System and the 362 
practice of the reminder method for erlotinib intake.34 The use of the reminder method was noted in more 363 
than 60% of patients receiving capecitabine at cycle 1 (61.5%, n=47), 3 (66.2%, n=44) and 5 (73.2%, 364 
n=41).37 365 
 366 
Despite the patients’ determination to precisely adhere to the prescribed medicine plan, patients identified 367 
barriers that could interfere with the adherence process. These include uncertainty in taking the correct 368 
number of tablets, skipping the exact time for intake, disruption in their daily routine and running out of 369 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
pills.35   Thirteen percent of patients (n=10) did not adjust the administration of capecitabine with meal 370 
times at cycle 1, a behaviour that increased by 10.9% towards cycle 5.37 This is comparable with 21% 371 
(n=8) of patients in the study by Timmers et al. (2015) who did not follow the advice of taking erlotinib 372 
under fasting conditions at 1 month. Using the generalised estimated equations, the occurrence of ocular 373 
symptoms (p=0.031) and stomatitis (p=0.005) were found to be significantly increased with incorrect 374 
intake of erlotinib without food.34              375 
 376 
(c) Medicine adverse events  377 
Adverse events were considered as one of the most challenging aspects of living with antineoplastic 378 
medicines. Patients referred to different adverse effects which ranged from minor to severe life-379 
threatening effects with the psychological and physical impact of these adverse effects  affecting the 380 
patients’ quality of life.28,30,32,35,36 A cognitive decline manifested as lack of concentration, deteriorating 381 
memory and dizziness was noted during and after antineoplastic treatment.30,35 Few participants reported 382 
of suffering from mild cognitive impairment described as "empty head" and "fog" which adversely 383 
affected their concentration.36 A few patients considered it strange to suffer from symptoms caused by the 384 
treatment and not from the actual illness. 30 385 
 386 
The extent and severity of adverse effects due to antineoplastic treatment played a huge role in many 387 
patients’ attitudes.29,33 A female patient expected to feel better with every chemotherapy cycle however 388 
she was frustrated when she started feeling side effects again.28 All patient-reported symptoms were 389 
reported to worsen from baseline to 1 month of treatment with erlotinib (with the exception of headache). 390 
Rash, fatigue and cough were the three most common patient-reported symptoms after 2 months.34 Thirty 391 
three percent of patients blamed side effects for the discontinuation of treatment with capecitabine prior to 392 
completion of the 5th cycle. The commonest patient-reported symptoms with capecitabine at cycle 5 were 393 
hand and foot syndrome, fatigue and flatulence In view that these patients had already reported the 394 
symptoms at baseline, were pre-treated and/or receiving capecitabine concomitantly with 395 
oxaliplatin/irinotecan, it is difficult to attribute these adverse effects solely to capecitabine. 37 396 
The majority of patients were still experiencing side effects after stopping treatment, with effects being 397 
cumulative and worsening over time. However, several patients were surprised to experience relatively 398 
few side effects during their course of chemotherapy, both for orally and parenterally administered 399 
antineoplastic treatment.31 400 
 401 
The aspect of “suffering” is so ingrained with the experience of chemotherapy that it is not even 402 
recognised as an adverse effect of treatment.31 Hence patients failed to recognise adverse effects from 403 
these medicines and refrained to inform the healthcare professionals about the occurrence and severity of 404 
adverse effects they experienced.28,32,35 The patient’s ability to tolerate the adverse effects is associated 405 
with the concept of making an effort to achieve cure or disease control and may be considered as the 406 
“price to pay” for treatment efficacy.32 Patients face adverse effects differently, they either accept to 407 
support their adverse effects and have a fatalist attitude or they resort to complementary medicine such as 408 
phototherapy, homeopathy and hypnotism. The focus groups discussions revealed that patients wait 409 
between 3 and 8 days prior to consulting medical advice. Some cancer patients even tried to hide or 410 
minimise their adverse effects by either not considering them as severe or by preferring not to talk about 411 
them.32,35 The latter may be the result of feeling afraid that the oncologist would change their treatment 412 
and hence reduce the possibility of a positive response. Few patients felt uncomfortable to speak about 413 
adverse effects during every appointment or to discuss specific intimate adverse effects such as vaginal 414 
dryness.30, 32, 35  415 
 416 
(d) Medicine and social burden  417 
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Despite having treatment, patients put all their efforts to be as positive as possible and lead a normal life. 418 
They realised the significance of every day and felt determined to appreciate their lives.30,36  “But because 419 
of the experience of illness, I realize how precious each day and normal life is.” 30 420 
 421 
Antineoplastic medicines affect the patient’s social life which is directly related to their quality of life. 422 
Patients experienced social isolation often due to altered relationships with family members and 423 
friends.29,30,35,36 This may be the result of adverse effects, complex treatment regimen or social stigma. As 424 
treatment became the focal point of the cancer patients’ lives, this also dominated both their social and 425 
family life. “I stopped playing with the orchestra in November of last year. That also has something to do 426 
with (name of medication); I got shaky and it had a few other side effects than with (intravenous) 427 
chemo.”35 Patients described this period as hard to get through and they focused all their efforts on their 428 
feelings. “And then there was the constant worry that the lab tests wouldn’t be good so that everything 429 
would have to be postponed, and my whole life was about this..”30  430 
 431 
In contrast, cancer patients recognised the support provided by family members for proper medicines use 432 
and the benefits of support groups. 29, 30, 33, 35, 36 The illness was described as a dramatic, traumatic and 433 
insane experience for the family. Family members offer paramount support to cancer patients, with the 434 
role of the spouse often considered as a “lifeline”.30 The partners were specifically identified as providing 435 
aid in the patients’ daily life such as doing the household chores as this allows the patients to rest when 436 
they felt tired.35 However there were other patients who felt as if their family did not take any extra 437 
consideration. The necessities of time and support to the patient from their relatives was usually 438 
overlooked, demonstrating the importance that relatives are aware of the patient’s requirements.30 439 
 440 
Patients also spoke about the impact of treatment on the patients’ work and financial income bringing 441 
about instability in life.  “Chemotherapy brings a lot of anxiety, because I don’t know if I can accept an 442 
order for or not. You know, there is no lack of work, but if you don’t deliver as promised the costumers 443 
forget about you. It’s bad time for work now…. But it’ll become better.”28 Patients, predominantly 444 
females, voiced a sense of gratitude for being granted sick leave during their treatment period. This 445 
provided time to completely devote their life to themselves. Patients disclosed their difficulties in 446 
returning back to their workplace. They described feeling pressured from society and healthcare 447 
professionals to return to their workplace as early as possible. The patients’ inner worry was that their 448 
employer expected to receive the same work output like before their diagnosis. Some women explained 449 
that specific work environments, such as working with children, may result in a higher risk of contracting 450 
infections. This may have contributed to their decision not to return to work during treatment. Some 451 
women narrated that when they spoke about cancer at the work place; this proved to be taken negatively 452 
both by employers and work colleagues.30 “But then I noticed, and when I came back and started to work 453 
full-time my boss came to me and said that this position I had applied for had gone to someone else 454 
because I had to think of my illness.”30 Those cancer patients who persisted with the working life had 455 
noted that work became important part of life and aided them to detach themselves from the illness itself. 456 
28,30
  457 
 458 
(e) Healthcare associated medicine burden 459 
Challenges associated with the complexity of the healthcare system were identified. Healthcare 460 
professional-patient relationships,29,30 patient-patient relationships,29 healthcare support29,30 and provision 461 
of information30 were commonly described.  Cancer patients looked for professionalism and traits such as 462 
empathy, respect and good support from healthcare professionals. The support offered by healthcare 463 
professionals was overall rated as positive.29,30  “Well the important thing is of course how they care for 464 
you, and not that it has to be so incredibly professional so that, that…Empathy is alpha and omega. And I 465 
think they are good and I always tell them that when they ask.”30 Provision of good quality information 466 
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from healthcare professionals delivered at the appropriate time was considered to be important and made 467 
a positive effect in the patients’ experiences. In fact, patients felt the large amount of information 468 
delivered, especially during the meeting when the oncologist broke the news about their diagnosis, as 469 
very “stressful”.29,30,32 Patients described that healthcare professionals should consider each patient to 470 
know nothing about the disease and the treatment and fulfil their information needs with plain, correct 471 
and clear material.30 472 
Cancer patients identified transportation, distance to hospital for multiple visits, hospital waiting time, 473 
companionship with caregivers to treatment and financial burden as barriers to treatment. These 474 
difficulties decreased the patients’ enthusiasm to continue long-term maintenance treatment with 475 
antineoplastic maintenance.29,33 “I live alone as well, and every time I come for chemo or transfusions I 476 
have to have someone bring me. So that would—if I had to come real frequently that would put a 477 
hardship on.”33 Patients commented on the lack of tranquil hospital environment and individualised 478 
support by hospital staff. Although the patients receiving oral antineoplastic treatment in the comfort of 479 
their own home was considered to be a major advantage, they complained of insecurity about not 480 
receiving professional counselling and support at home.29, 35  481 
 482 
Some patients felt that other patients may offer companionship and moral support particularly when they 483 
accompany one another during treatment cycles. During the chemotherapy outpatient clinic, cancer 484 
patients interacted with each other and also served as a network of support. They would transmit to each 485 
other positivism, strength and a feeling of unity.28, 30 “Yes, it is very important to have someone to share 486 
this with because other people do not know what you’re talking about. You can explain but they do not 487 
know what chemotherapy treatment is.”30 Whilst being an in-patient to receive parenteral treatment, one 488 
patient even praised the consideration of healthcare professionals who ensured patients of similar age and 489 
treatment share the same hospital room. However others mentioned the negative psychological impact in 490 
the announcement that a patient in their group is suffering from a terminal disease which will reasonably 491 
result into death within a short period of time.  “For the first treatment I was placed in a four-bed room 492 
and I remembered that I thought it was so hard, really hard; for one thing, I had just found out my 493 
diagnosis....and then you just see old people and it gets so obvious what am I doing here. You know it was 494 
absolute, I didn’t want to be there with all the drainage bags they had, and it was hard. But since then it 495 
has been so nice because I was able to change rooms and she (another patient) is the same age as me; we 496 
do the treatment together and I think it’s great that they have scheduled us together and that we can share 497 
a room.” 
29 
 498 
 499 
Patients enquired about the lack of available treatments despite the ongoing research in oncology.31,33 A 500 
cancer patient made reference to fluorouracil, a standard antineoplastic medicine which has been available 501 
for the past 20 years and is still in use; hence can be considered as quite an old drug. He considered this as 502 
a bad thing in the light that continuous research is being conducted in this field and remarked, “Surely we 503 
can do better than that!”31 504 
Discussion 505 
The systematic review indicates that none of the published papers provided a standard definition of the 506 
patients’ lived experience with medicine. The systematic review showed that PLEM is a highly subjective 507 
and complex concept, with a lot of considerations. Hence this systematic review supports the model 508 
which offers a better framework for PLEM. The model developed by Mohammed et al. (2016) is 509 
comprehensive and encapsulates the important aspects in PLEM. This systematic review identified lack of 510 
studies with none of the identified studies making use of the PLEM model. Despite the inclusion of a 511 
small number of studies in this systematic review, this has captured all the themes related to medicine-512 
related beliefs, medicine-taking practice and medicine-related burden mentioned in the model by 513 
Mohammed et al. (2016). Hence, this model is likely to be transferable to the oncology setting with slight 514 
modifications. 17 515 
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 516 
Collectively researchers provided an extensive account on beliefs, practice and burden of patients 517 
receiving different antineoplastic medicines. Patients considered this treatment either as hope or worse 518 
than the illness itself. This systematic review showed that patients’ treatment decision was highly 519 
influenced by the healthcare providers’ and carers’ preferences. Patients should be informed about all 520 
treatment options and be part of the treatment decision in order to be recognised as equal partners in the 521 
healthcare team.38,39  522 
The introduction of oral antineoplastic agents has altered the outlook of provision of cancer treatment 523 
from a controlled monitored procedure in hospital for parenteral treatment to individualised responsibility 524 
in the patient’s home. This created a major shift in the roles of healthcare professionals mostly doctors, 525 
nurses and pharmacists onto patients and carers.40 Experienced patients who had received different 526 
antineoplastic treatments argued that intravenous chemotherapy necessitates an autonomous behaviour 527 
solely for managing side effects. On the other hand, the medicine-taking practice together with the 528 
monitoring of adverse effects of oral antineoplastic is more dependent on the patient’s autonomy. This 529 
systematic review showed that patients voiced their concern that information about treatment was given 530 
by healthcare professionals at a time when they were not able to fully comprehend and pose the necessary 531 
questions. Hence patients expressed their need of treatment-specific education in a consistent and 532 
practical manner for the complex antineoplastic treatment regimens.41  533 
 534 
Research showed that patient adherence to long term treatment was no more than 50% but seems to be 535 
higher in case of antineoplastic treatment. Although there are multiple reasons for this, it is highly 536 
associated with the perceived fatal implications of cancer.42 This was consistent with our systematic 537 
review where patients were noted to be highly adherent to treatment. Patients noted that forgetting to take 538 
the treatment was often due to an alteration in their daily routine such as going on vacation or visiting 539 
friends. They also described of being in doubt whether they had taken the right amount of tablets or 540 
whether they had failed to take the treatment at the exact time.32,35 Patients who had received various 541 
antineoplastic treatments had a risk of developing more secondary effects which may result in lack of 542 
adherence and poor concordance to the current prescribed treatment. Therefore, the patients necessitate 543 
specific advice when changing from one medicine to another.32  544 
 545 
This systematic review identified misconceptions that patients had about treatment especially in relation 546 
to efficacy. From a biomedical perspective, chemotherapy in oral formulation has similar efficacy as 547 
parenteral and hence is certainly not associated to treat less ‘serious’ cancers. Other patients believed that 548 
they were suffering from a milder cancer compared to other patients as they were receiving oral 549 
chemotherapy.31 Patients did not always understand or were provided with the rationale behind certain 550 
requirements of the treatment. For instance, breaks between treatments were either medically prescribed 551 
interruptions according to treatment protocol or due to the occurrence of adverse effects. Patients 552 
associated these breaks as periods of relief and freedom from constraints to the medicine plan such as 553 
‘holidays’ or as burdensome periods with worsening of adverse effects and fear of recurrence.33,35 This 554 
emphasised the importance of involving patients in decision making about their treatment and the 555 
explanation of treatment.32 556 
 557 
During the treatment journey patients are not only experiencing physical effects but also psychological 558 
effects with a myriad of emotions. As a result of fear of modification or discontinuation of treatment, 559 
patients delay in reporting adverse effects to healthcare professionals.32,35 However, patients who 560 
experienced minimal adverse effects thought that their treatment was not effective. This induced 561 
unnecessary concern and stress to the patients.28,30 562 
 563 
Consistent with other studies, nausea and vomiting are the most common adverse drug reactions 564 
experienced by patients. Studies showed that patients required increased doses of anti-emetic treatment in 565 
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order to manage these symptoms.  Due to the common occurrence of adverse effects with antineoplastic 566 
medicine, it is vital that patients would be able to identify these toxicities and be advised on what 567 
measures to follow.29,36,41 Reasons provided by patients about lack of reporting of adverse effects were 568 
uncertainty about severity of adverse effects, fear of withholding treatment and waiting for the next 569 
appointment rather than contacting the healthcare professional immediately. Delayed reporting of adverse 570 
effects to healthcare professionals may lead to a detrimental effect to the patients themselves.32   571 
Cancer treatment transformed and dominated the patient’s social and family life. The patients 572 
acknowledged support from family members, peers, support groups and healthcare professionals during 573 
their treatment and also their need to develop coping skills.29,30,33,35,36 This will identify the importance of 574 
the provision of holistic care to the patients with cancer at all stages of the treatment journey, taking into 575 
consideration their physical, psychological, social and spiritual well-being. This systematic review will 576 
empower healthcare professionals to consider all the aspects of PLEM in their practice in the area of 577 
cancer treatment in order to help patients achieve a better quality of life during the treatment journey. The 578 
complexity of cancer treatment necessitates more patient involvement. Interprofessional collaboration 579 
between healthcare professionals in primary and tertiary settings together with the carer are needed to 580 
ensure services that meet the patient’s needs. Educational and motivational strategies adapted and re-581 
enforced at different time-points during the treatment are necessary to address issues particularly related 582 
to aspects of burden. 583 
 584 
Future research should focus on interventions that may be practiced by healthcare professionals to 585 
enhance patient’s empowerment and encourage patients to take more active role in their cancer treatment. 586 
Studies should also be conducted on patients refusing to initiate or discontinue treatment with 587 
antineoplastic medicines to understand their beliefs, perceptions and attitudes.  588 
Limitations  589 
This systematic review followed a comprehensive search strategy in six databases since their respective 590 
inception. Identification of studies and data extraction was performed by 2 independent reviewers so as to 591 
reduce bias and improve the rigour. However this systematic review has its limitations. The included 592 
studies had to focus on the whole concept of PLEM, which means that all 3 themes of medicine-related 593 
burden, medicine-taking practice and medicine-related beliefs had to be discussed in the same 594 
publication. This is due to the overwhelming amount of publications focusing on one particular aspect and 595 
to offer researchers a broad complete picture of the inter-relationship between the 3 themes in a particular 596 
setting experienced by the patient. Studies that assess adherence to antineoplastic agents have been 597 
conducted but this systematic review included only those studies that also involved medicine-related 598 
beliefs and medicine-related burden. Therefore adherence to antineoplastic medicines is being discussed 599 
in relation to a holistic aspect of the patients’ lived experience with medicines. This systematic review 600 
relied on secondary data and combined data from different methodologies and of different quality.  Hence 601 
this resulted in the provision of limited detail to the authors and increased the element of bias in the 602 
interpretation of the results. The review only included studies published in English, which might have 603 
resulted in publication bias. In addition, grey literature including conference abstracts was not included in 604 
this review. Since the review included studies conducted in different countries and settings, patients 605 
provided their experiences based on their healthcare systems which may vary from country to country. 606 
Although all patients were suffering from solid tumours and receiving antineoplastic medicines, different 607 
cancer types may require diverse treatment regimens which vary in complexity. This may lead to 608 
increased heterogeneity of the review results. Various confounding factors such as patient characteristics, 609 
comorbidities, environmental factors and time-points in the treatment journey when the study was 610 
conducted may have affected the findings.  611 
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Conclusion 612 
This systematic review elicits a comprehensive assessment of the patients’ needs which is crucial for  613 
patient-centred care. The adapted model of PLEM for patients with solid tumours receiving antineoplastic 614 
medicines explains the dynamic processes and socio-cultural influences that affect medicine-related 615 
beliefs, medicine-taking practice and medicine-related burden. It shows that patients undergo a 616 
continuous process of reinterpretations of the phenomenon along the treatment journey. 617 
 618 
Patients are experts by experience as they provide a unique perspective on their disease state and required 619 
care. The understanding of the patients’ experience with the antineoplastic medicines sheds light on the 620 
patients’ needs and support services needed during this journey. This will ultimately lead to better health 621 
outcomes and improved quality of healthcare services. 622 
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Table 1 Information about the studies included in the systematic review arranged in chronological order 
 
Study 
[Authors, 
year, 
country] 
Stated aim(s) and 
objective(s) 
Setting and 
number of 
respondents 
 
Study design  Method of data 
collection Data analysis Key findings 
Yokoyama 
dos Anjos 
and Zago, 
2005, Brazil 
To understand the meaning 
of the chemotherapy from 
the patient’s point of view  
Oncology 
hospital and 
patient’s home, 
n=1  
Qualitative 
ethnographic case 
study  
• Semi-structured 
interviews 
• non-structured 
observations  
• patient’s field diary  
Interpretative 
anthropology 
 
Seven unities of meaning were identified:                                                       
1. discovery of cancer and search for assistance,                              
2. knowledge about cancer,                                                                              
3. trajectory of chemotherapy,                                                                
4. networks of support,                                                                               
5. lack of control of one’s life,                                                                              
6. uncertainty about the future,                                                         
7. expectation in the future.     
 
The patient’s view on her experience with cancer 
chemotherapy as “the loss of the control over one’s 
life” were summarised. The study emphasised the need 
for nurse care to follow up the patient throughout the 
whole process and offer resources to the patient to 
resume control of her life during this critical period. 
 
Bergkvist 
and 
Wengstrom, 
2006, 
Sweden  
To acquire a deeper 
understanding of cancer 
patients’ symptom 
experiences with focus on 
nausea and vomiting 
during chemotherapy 
treatment and the 
consequences these have 
on daily life 
Oncology 
hospital, n=9  Qualitative study 
Semi-structured 
interviews  Content analysis 
 
Five main categories in the experience of 
chemotherapy treatment were identified:                                                                        
1. before cancer diagnosis,                                                                 
2. being ill—consequences on daily life,                                      
3. going through chemotherapy treatment,                            
4. coping with treatment,                                                               
5. after treatment—looking forward to a normal life.  
 
The study describes that the experience of receiving 
chemotherapy is a process that evolves over time. The 
findings suggest that experiences of nausea and 
vomiting during chemotherapy treatment have a 
profound effect on the cancer experience and thus may 
influence future decisions relating to new treatment. 
 
 
Browall, 
Gaston-
To describe the experience 
of postmenopausal women 
Oncology 
hospital and Qualitative study 
 
Narrative interviews Content analysis 
 
Four themes were identified:                                                               
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Johansson 
and 
Danielson, 
2006, 
Sweden  
with breast cancer who 
undergo adjuvant 
chemotherapy treatment 
patient’s home, 
n=20  
with one open question  1. the fear of the unknown,                                                                      
2. affects on body and mind,                                                                      
3. to get by,                                                                                                     
4. a transformed life.                     
                                                                                                  
The participants described feelings of imbalance in 
their relationships due to lack of support from those 
close to them. The support from healthcare 
professionals was experienced both positively and 
negatively; with most of the participants revealing 
variations in the healthcare professionals’ attitude, 
knowledge, and empathy. Women who decided not to 
work during the treatment felt pressure from society 
and healthcare professionals to get back to work as 
soon as possible. The participants expressed a feeling 
of not being afraid of dying but wanted more time to 
prepare themselves.  
 
Bell, 2009, 
Canada  
To explore patients’ 
perceptions of adjuvant 
chemotherapy 
Cancer support 
group, n=8  Ethnography 
• Semi-structured 
interviews 
• participant 
observation at the 
support group 
meetings  
 
Thematic 
analysis 
 
Three themes were identified:                                                                                                
1. Hurting the good cells & really hurting cancer cells,                  
2. Getting a “full dose”,                                                                          
3. Oral vs  intravenous chemotherapy.                                                 
 
A cultural model of chemotherapy was noted which 
stressed the value of suffering and pain as means of 
monitoring treatment effectiveness and even the 
possibility of cure. This framework differs from 
biomedical understanding of treatment in various 
aspects, with implications on anxiety levels 
experienced by the patients and the risk of recurrence.  
 
Regnier 
Denois, 
Poirson, 
Nourissat, 
Jacquin, 
Guastalla 
and 
Chauvin, 
2011, France  
 
To describe and 
understand existing 
practice for capecitabine 
and to evaluate the 
perceptions and 
descriptions of patients and 
oncologist about the 
prescription of 
capecitabine  
2 oncology 
hospitals, n=45 Qualitative study 
• Semi-directive 
interview 
technique to 
patients and 
oncologists 
• observational 
phase with patients 
• focus group 
interviews with 
patients 
 
 
 
Content analysis 
 
Adherence, which in this study was defined as being 
against not taking their treatment, generally seemed 
satisfactory. Results showed a wide diversity in the 
prescribers’ practices, who often made decisions based 
on their experience of practice guidelines for 
intravenous chemotherapies. Although the results for 
the patients do not suggest deliberate non-adherence, 
they show poor observance of the dose schedule. The 
study identified the patient’s inability to recognise and 
report important signs of harmful toxicity. 
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Gerber, 
Hamann, 
Rasco, 
Woodruff 
and  
Craddock 
Lee, 2012, 
United 
States  
To gain insight into patient 
perceptions of 
maintenance chemotherapy 
for advanced 
non-small cell lung cancer 
Hospital 
(inpatient), n=47  Qualitative study 
 
Focus group  
Thematic content 
analysis 
 
Five themes were identified:                                                                       
1. survival benefits, disease control, and “buying 
time”,                                                                            
2. the importance of  “doing something”,                                         
3. quality of life concerns,                                                                                                                 
4. the role of provider opinion/preference, 
 5. the importance of logistics. 
 
Timmers, 
Boons, 
Moes-ten 
Hove, Smit, 
van de Ven, 
Aerts, Swart, 
Boven and 
Hugtenburg, 
2015, 
Netherlands  
To assess adherence to 
erlotinib treatment and 
evaluate experiences of 
patients as well as the 
relationship between 
medicine adherence, 
erlotinib exposure and 
symptoms 
12 hospitals, 
n=62  
 
Prospective 
observational cohort 
study 
• Patients reported 
questionnaires  
• patients’ medical file 
• adherence measured 
with medication 
event monitoring 
system (MEMS)  
• blood samples   
Mann–Whitney 
test, 
Fisher exact test 
 
According to the Belief about Medicines Questionnaire 
(BMQ), 40% (n=25) of patients were classified as 
“accepting” treatment with erlotinib. 55% (n=34) of 
patients who had started their treatment with erlotinib, 
considered their treatment to be of high necessity and 
high concern. MEMS data of 55 patients revealed a 
mean adherence of 96.8 ± 4.0 %. Over one-third of 
patients had an adherence rate <95 %. At 1 month, 21 
% of patients did not always correctly take erlotinib 
without food. Associated risk factors were older age, 
suboptimal adherence, ocular symptoms and stomatitis 
(all p < 0.05). After 1 month of treatment, fatigue 
(91%) and rash (86%) were the most common 
symptoms reported. AUCss of erlotinib was higher in 
patients with rash and patients with moderate–severe 
anorexia (both p < 0.05). 
 
Gassmann, 
Kolbe and 
Brenner, 
2016, 
Switzerland  
 
To explore the experiences 
of patients undergoing oral 
chemotherapy and 
investigate the impact of 
oral chemotherapy on their 
daily life 
Outpatients 
clinic of an 
urban hospital, 
n=6  
Grounded theory Open interviews  
Constant 
comparison 
coding and 
categorising in 
line with 
paradigm model 
 
Participants reported physical and emotional reluctance 
towards oral chemotherapy as well as toxic side effects. 
Feeling responsible emerged as a core phenomenon 
with influences from context and intervening 
conditions. All participants intended to adhere to 
treatment despite being a challenging task due to 
complex treatment regimen. Belief in the effectiveness 
of the therapy was a strengthening factor. Participants 
struggled between the necessity of adhering to oral 
chemotherapy and the practicality as well as emotional 
difficulties of daily life. Hence, patients developed 
coping strategies during the treatment journey. In 
consequence, oral chemotherapy was found to be 
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omnipresent by determining the participants’ thoughts 
and daily life. 
 
Komatsu, 
Yagasaki, 
Yamauchi 
and 
Yamauchi, 
2016, Japan  
To explore the experiences 
of patients with breast 
cancer who had received 
chemotherapy to 
understand how they 
perceived the impact of the 
treatment on their daily 
lives 
Outpatients of 
breast or 
oncology centre 
clinic in a 
hospital, n=17 
Grounded theory Semi-structured interviews  
Analysis of 
transcripts by 
first coding and 
then labelling the 
meanings. 
Subcategories 
were identified 
to lead 
categories. Core 
categories 
emerged by 
connecting 
categories and 
subcategories. 
 
Patients created personal safety nets for physical, 
emotional and social contexts during chemotherapy, 
even though they found everyday life to be more 
challenging because of the disease and side effects. 
Through their safety nets, the participants felt more 
confident and in control of their lives and were willing 
to take a positive approach towards making their lives 
meaningful. In anticipation of side effects of 
chemotherapy, participants "hibernated" and consumed 
minimal amount of energy. They also created a 
protective inner space in which they were able to 
tolerate fear and anxiety and exert self-control. In 
maintaining their daily routines, patients felt more 
confident to balance their lives and illness and helped 
them to tolerate uncertainty.  
 
Timmers, 
Boons, 
Mangnus,                        
van de Ven, 
Van den 
Berg, Aart 
B, Swart, 
Honeywell, 
Peters, 
Boven, 
Hugtenburg, 
2016, 
Netherlands 
To get insight into 
patients’ experiences with 
the use of capecitabine in 
daily practice and the 
various aspects that govern 
adherence 
10 hospitals, 
n=92  
 
Prospective 
observational cohort 
study 
• Adherence assessed 
using a pill count, 
pharmacy data and 
dosing information 
obtained from the 
patients’ medical file 
(PPP method) 
• self-reported 
adherence measured 
using the Medication 
Adherence Report 
Scale. 
• patients reported 
questionnaires  
• blood samples  
 
X2-test, 
Fisher’s exact 
test, 
Logistic 
regression 
 
Most patients (91%) had an adherence rate of ≥95 and 
≤105%. Symptoms were frequently reported and the 
dosing regimen was adjusted by the physician at least 
once in 62% of patients (n=57). According to BMQ, 
50% (n=46) of patients were classified as “accepting” 
capecitabine. These patients were associating their 
medicine with a high necessity and low concern prior 
to initiation of treatment. 44% (n=40) patients who had 
started their treatment with capecitabine considered 
their treatment to be of high necessity and high 
concern. According to the Brief Illness Perception 
Questionnaire (IPQ), patients were found to believe 
that treatment with capecitabine will help their illness 
and achieve treatment control. This is evidenced by the 
mean value which improved from baseline (7.8±1.8) to 
cycle 5 (8.0±1.6). 
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Figure 1 Conceptual model of the patients’ lived experience with medicine (PLEM) as developed by                   
Mohammed et al. (2016). The model shows the complexity of PLEM and an inter-relationship between 
medicine related burden, medicine related beliefs, medicine taking practice.  
Adopted from: Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients’ lived 
experience with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open. 
2016;6:e010035. 
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Figure 2 Prisma flow diagram showing the inclusion and exclusion of studies identified for the systematic 
review. Reasons for the studies being excluded are also provided. Adapted from Prisma 2009 flow diagram.27 
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Figure 3 An adapted model of PLEM for patients with solid tumours receiving antineoplastic medicines
